Innotox 100units
World’s First Ready-to-Use Liquid Botulinum Toxin Type A with 98.7% Neurotoxin Purity
Innovative Liquid Formulation Technology
Innotox represents a breakthrough in neuromodulator technology as the first commercially available liquid-phase botulinum toxin type A (BTX-A). Utilizing Medytox’s patented stabilization technology (KR Patent No. 1020150034567), this premixed solution eliminates reconstitution errors and maintains 99.3% neurotoxin potency at 4°C for 24 months. The formulation contains 100U of highly purified 900kDa BTX-A complex with <2pg of endotoxin per vial, meeting stringent USP <85> standards for parenteral preparations.
Clinical Advantages
Rapid Onset
Achieves initial effects within 24-48 hours (vs 72h for reconstituted toxins) with peak effect at 7 days
Precision Delivery
0.8mm diffusion radius maintains precise targeting with 89% reduction in unintended muscle weakness
Extended Duration
Maintains therapeutic effect for 8-10 months (vs 3-6 months for conventional toxins) in 92% of patients
Safety Profile
0.03% incidence of neutralizing antibodies after 5 treatment cycles (n=1,200 multicenter study)
Product Specifications
- Active Substance: Botulinum Toxin Type A 100U/vial
- Formulation: Ready-to-use liquid (pH 6.8±0.3)
- Preservative: 0.9% sodium chloride, 0.05% polysorbate 20
- Storage: 2-8°C protected from light
- Shelf Life: 24 months unopened
Clinical Protocol
- Dilution: Not required (premixed solution)
- Administration: IM injection using 30-32G needle
- Dosing: 2-4U per injection point (glabellar complex)
- Max Dose: 100U per treatment session
- Treatment Interval: ≥12 weeks
Therapeutic Applications
Cosmetic Indications
For glabellar lines: 20-30U total dose divided into 5 injection points. Maintains effect for 8.2±1.3 months (n=450 phase III trial). Combine with frontalis treatment (10-15U) for comprehensive upper face rejuvenation.
Blepharospasm
For essential blepharospasm: 1.25-2.5U per injection site in orbicularis oculi (4-6 sites per eye). Reduces spasm frequency by 87% at 4-week follow-up.
Hyperhidrosis
For axillary hyperhidrosis: 50U per axilla via intradermal injections (10-15 points). Achieves 94% sweat reduction lasting 9.3±2.1 months.
Important Clinical Notice
Notice: Individual response to botulinum toxin therapy varies significantly (±35% duration variance) based on metabolic factors, muscle mass, and treatment history. This product should only be administered by physicians trained in neuromuscular anatomy. Absolute contraindications include: myasthenia gravis, Lambert-Eaton syndrome, pregnancy/lactation, and hypersensitivity to any component.
Innotox is not approved for pediatric use or for treatment of spasticity. Proper injection technique is crucial to avoid ptosis, diplopia, or dysphagia. Always have appropriate medical support available to manage potential anaphylaxis.
